<DOC>
	<DOCNO>NCT01225146</DOCNO>
	<brief_summary>The RAVE 2 trial phase I , open label , 12-month trial intravitreal ranibizumab 2.0 mg patient ischemic CRVO either previously treat ranibizumab treatment naïve .</brief_summary>
	<brief_title>Study 2.0 mg Ranibizumab Subjects With Ischemic Central Retinal Vein Occlusion ( RAVE2 )</brief_title>
	<detailed_description>The devastate complication ischemic CRVO development anterior segment neovascularization result morbidity neovascular glaucoma . This complication appear directly correlate intraocular VEGF level . Currently proven treatment decrease formation rubeosis . Current management disease consist pan-retinal photocoagulation significant anterior segment neovascularization become manifest . This treatment destroy peripheral retina ( peripheral retinal field ) presumably work eventually lowering ocular VEGF level cause secondary regression rubeosis . As ranibizumab block VEGF , treatment deliver intraocularly may prevent neo-vascular glaucoma preserve peripheral visual field patient population . A high dose ranibizumab may allow long duration treatment effect potentially efficacy leading good outcome patient somewhat treatment resistant need continual therapy . Nonclinical early clinical data indicate high dos ranibizumab include 2.0 mg safe tolerate patient .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Pathologic Processes</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects eligible follow criterion meet : Ability provide write informed consent comply study assessment full duration study Age &gt; 18 year For patient previously treat ITV ranibizumab ( Cohort 1 ) : 6 intravitreal injection ranibizumab presence persistent edema minimum 6 ranibizumab injection follow RAVE 1 . For treatment naïve ( Cohort 2 ) : Ischemic CRVO within 3 month enrollment per follow inclusion criterion Three follow clinical test must present demonstrate ischemic CRVO : VA 20/200 bad RAPD 0.9 LU bad Loss 12e isopter Goldmann Visual field ( Kwon et al . 2001 ) ERG demonstrate b wave amplitude le 60 % A wave Capillary nonperfusion great 50 DA Subjects meet follow criterion exclude study : IOP 30 mm Hg Any previous retinal laser photocoagulation study eye treatment naive Any previous intravitreal injection study eye ( triamcinolone ) treatment naive Any previous vitrectomy study eye ( posterior anterior associate vitreous loss cataract surgery ) Intracapsular cataract extraction ( posterior capsule need present ) Previous history retinal detachment study eye Any previous radiation treatment head/ neck Inability ass iris neovascularization ( corneal opacity preclude gonioscopy ) Significant cardiovascular disease cancer would prevent followup visit completion 12 month study Significant diabetic retinopathy fellow eye ( diabetic macular edema , proliferative diabetic retinopathy , highrisk nonproliferative diabetic retinopathy ) Pregnancy ( positive pregnancy test ) Participation another simultaneous medical investigator trial Ocular disorder study eye may confound interpretation study result , include retinal detachment , macular hole , choroidal neovascularization cause ( e.g. , DME AMD , ocular histoplasmosis , pathologic myopia ) Concurrent disease study eye could compromise visual acuity require medical surgical intervention study period Aphakia absence posterior capsule study eye Previous violation posterior capsule also exclude unless occur result YAG laser posterior capsulotomy association prior , posterior chamber intraocular lens implantation History idiopathic autoimmune uveitis either eye Structural damage center macula study eye preexist CRVO likely preclude improvement visual acuity follow resolution macular edema , include atrophy retinal pigment epithelium , subretinal fibrosis , laser scar ( ) Vitreomacular traction epiretinal membrane study eye evident biomicroscopically OCT Ocular inflammation ( include trace ) study eye Infectious blepharitis , keratitis , scleritis , conjunctivitis ( either eye ) current treatment serious systemic infection Spherical equivalent refractive error study eye 8 diopter myopia ( For patient refractive cataract surgery study eye , preoperative spherical equivalent refractive error 8 diopter myopia allow ) Systemic Conditions Uncontrolled Blood pressure exceed diastolic pressure 100 mm Hg ( sit ) screen period Uncontrolled diabetes mellitus Renal failure require dialysis renal transplant Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch . Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial History disease , metabolic dysfunction , physical examination finding , finding give reasonable suspicion disease condition contraindicate use investigational drug , might affect interpretation result study , render subject high risk treatment complication Other History allergy fluorescein , amenable treatment Inability obtain fundus photograph fluorescein angiograms sufficient quality analyze graded central reading center Inability comply study follow procedure History allergy humanize antibody component ranibizumab formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Ischemic</keyword>
	<keyword>Central</keyword>
	<keyword>Retinal</keyword>
	<keyword>Vein</keyword>
	<keyword>Occlusion</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Lucentis</keyword>
	<keyword>CRVO</keyword>
	<keyword>ISCRVO</keyword>
</DOC>